FBIOP sentiment intelligence

Precision Trading with Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Risk Zones

This article analyzes Fortress Biotech Inc.'s (FBIOP) Series A preferred stock, highlighting its neutral near and mid-term readings but a strong long-term positive bias. It identifies an exceptional 48.2:1 risk-reward setup targeting a 12.8% gain versus 0.3% risk. The analysis pr

Tone

Neutral 50/100

Event

Market update

Published

30 Jul 2026 00:50

Source

Stock Traders Daily

FBIO|Fortress Biotech Inc|Price:3.301|Chg%:-0.049

This article provides a comprehensive stock analysis of Fortress Biotech Inc (FBIO), highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Pharmaceuticals industry. It notes high institutional ownership and a "Buy" rating from multiple

Tone

Neutral 50/100

Event

Analyst action

Published

29 Jul 2026 21:40

Source

TradingKey

Press Release: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing

Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, a clinical-stage biotechnology company, has successfully completed a $130 million Series B financing round. Urica Therapeutics has an equity ownership stake in Crystalys Therapeutics, be

Tone

Neutral 50/100

Event

Deals and strategy

Published

28 Jul 2026 11:40

Source

Moomoo

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing

Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, in which Urica holds an equity position, closed an oversubscribed $130 million Series B financing. This funding will support the late-stage global clinical development and commercializat

Tone

Neutral 50/100

Event

Market update

Published

28 Jul 2026 11:00

Source

marketscreener.com

Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Fortress Biotech Inc (FBIO) by business segment. As of April 2, 2025, the company's products Targadox®, Exelderm®, and Ximino® generated revenues of $3.20M, $2.40M, and $287.00K respectively, comprising 3.79%, 2.83%, and 0.34% of the

Tone

Neutral 50/100

Event

Earnings

Published

27 Jul 2026 14:11

Source

TradingKey

Fortress Biotech Inc (FBIO) Institutional Confidence

Fortress Biotech Inc (FBIO) has an institutional shareholding score of 3.00, ranking 92nd out of 155 in the Pharmaceuticals industry. The current institutional shareholding proportion is 18.14%, reflecting a 31.58% decrease quarter-over-quarter. James Simons is the largest instit

Tone

Neutral 50/100

Event

Market update

Published

27 Jul 2026 12:12

Source

TradingKey

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing

Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, in which Urica holds an equity position, closed a $130 million Series B financing. These proceeds will fund the late-stage global clinical development and commercialization of dotinurad,

Tone

Neutral 50/100

Event

Market update

Published

27 Jul 2026 12:11

Source

The Manila Times

Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Fortress Biotech Inc (FBIO), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdi

Tone

Neutral 50/100

Event

Market update

Published

27 Jul 2026 07:11

Source

TradingKey

Fortress Biotech, Inc. Revenue Breakdown – NASDAQ:FBIO

Fortress Biotech, Inc. (NASDAQ: FBIO) generated $63.26 million in revenue last year, with its Journey segment contributing the most at $61.86 million. The United States was the primary source of revenue, accounting for the entire $63.26 million. This shows a slight increase in ov

Tone

Neutral 50/100

Event

Earnings

Published

26 Jul 2026 22:40

Source

TradingView

Fortress Biotech Inc (FBIO) Income Statement

This article provides an income statement for Fortress Biotech Inc (FBIO), detailing its quarterly and annual financial performance. It includes metrics such as total revenue, cost of revenue, operating expenses, and net income, alongside year-over-year comparisons. The page also

Tone

Neutral 50/100

Event

Earnings

Published

26 Jul 2026 21:39

Source

TradingKey

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

This article provides details on the revenue breakdown for Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP). Last year, the company generated $63.26 million USD in total revenue, with its Journey segment contributing $61.86 million

Tone

Neutral 50/100

Event

Earnings

Published

26 Jul 2026 02:41

Source

TradingView

FBIO|Fortress Biotech Inc|Price:3.340|Chg%:-0.090

Fortress Biotech Inc (FBIO) is trading at $3.34, down 2.62%. The company's fundamentals are considered healthy with high growth potential, and its valuation is seen as fairly valued within the Pharmaceuticals industry. Analysts have rated it a "Buy" with a target price of $11.00,

Tone

Neutral 50/100

Event

Analyst action

Published

24 Jul 2026 20:39

Source

TradingKey

Fortress Biotech Inc (FBIO) Financial Health: Profitability & Balance Sheet Analysis

Fortress Biotech Inc (FBIO) has a robust financial score of 8.91, ranking 26 out of 155 in the Pharmaceuticals industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 22.06% and a net profit

Tone

Neutral 50/100

Event

Earnings

Published

24 Jul 2026 20:39

Source

TradingKey

Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)

Tone

Neutral 50/100

Event

Earnings

Published

23 Jul 2026 07:00

Source

Seeking Alpha

Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Support Amid Low Volume Trading - Modified Schiff

Tone

Neutral 50/100

Event

Market update

Published

21 Jul 2026 14:42

Source

dars.gov.et

Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Support Amid Low Volume Trading - Synthetic Short

Tone

Neutral 50/100

Event

Market update

Published

21 Jul 2026 07:00

Source

dars.gov.et

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

16 Jul 2026 07:00

Source

Market source

CNB0 Bond Coupon Profile — Rate & Payments

This article provides a brief overview of the CNB0 bond coupon profile, detailing its interest rate and payment structure. It highlights the importance of the coupon as the interest rate paid on a bond by Fortress Biotech, Inc. for its 9.375% Series A Cumulative Redeemable Perpet

Tone

Neutral 50/100

Event

Market update

Published

15 Jul 2026 03:13

Source

TradingView

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

12 Jul 2026 07:00

Source

The Globe and Mail

Fortress Biotech highlights its biotech portfolio strategy as a Nasdaq-listed micro-cap

Fortress Biotech, a Nasdaq-listed biopharmaceutical company, emphasizes its strategy of a diversified portfolio managed through subsidiary companies and partnerships. This approach focuses on licensing, clinical development, and eventual commercialization of novel therapeutics, p

Tone

Neutral 50/100

Event

Market update

Published

08 Jul 2026 19:27

Source

AD HOC NEWS

Mustang Bio (MBIO) Registration Filing Summary

Mustang Bio (MBIO) is a clinical-stage biopharmaceutical company focused on CAR T therapies, operating as a majority-controlled subsidiary of Fortress Biotech. The company has an accumulated deficit of $395.8 million, no product sales to date, and faces significant doubt about it

Tone

Neutral 50/100

Event

Market update

Published

07 Jul 2026 19:11

Source

Quartr

Fortress Biotech focuses on specialty pharma growth and licensing model

Fortress Biotech pursues a portfolio strategy in specialty pharmaceuticals, building and licensing therapies through its partner companies, and diversifying its pipeline to mitigate risk. The company focuses on specialty and rare disease markets, aiming for premium pricing and st

Tone

Neutral 50/100

Event

Market update

Published

07 Jul 2026 15:30

Source

AD HOC NEWS

Fortress Biotech Inc highlights its specialty pharma model as investors assess long-term prospects

Fortress Biotech Inc operates a specialty pharmaceutical and biotech portfolio strategy, utilizing a holding-style structure with multiple subsidiaries to develop product candidates across various disease areas like oncology and rare diseases. This approach aims to diversify risk

Tone

Neutral 50/100

Event

Market update

Published

03 Jul 2026 15:41

Source

Ad-hoc-news.de

Trading the Move, Not the Narrative: (FBIOP) Edition

This article provides an AI-driven analysis for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), highlighting weak near-term sentiment but strong long-term potential. It offers three distinct institutional trading strategies—P

Tone

Neutral 50/100

Event

Market update

Published

26 Jun 2026 05:52

Source

Stock Traders Daily

Form 4 Fortress Biotech Inc For: 24 June By Investing.com

This article announces the filing of Form 4 for Fortress Biotech Inc. on June 24. It is a brief report from Investing.com, providing basic information about the regulatory filing. The content focuses on the public disclosure of insider transactions for the company.

Tone

Neutral 50/100

Event

Regulatory and legal

Published

25 Jun 2026 22:11

Source

Investing.com South Africa